The filing application is based on improvements seen across key efficacy endpoints from the global phase III SatraGO-1 and ...

The FDA granted priority review to a supplemental biologics license application for Enspryng for thyroid eye disease, ...

Backed by data from the phase 3 SatraGO trials, satralizumab has the potential to offer patients a convenient, at-home treatment option.

Roche’s Enspryng (satralizumab), a thyroid eye disease (TED) treatment, has been accepted by the FDA and given priority ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental ...

An Iowa watchdog group says the EPA has stalled, or even scuttled, a nitrate review tied to health risks in drinking water.

Viridian Therapeutics receives US FDA approval for Lumvoa for the treatment of thyroid eye disease: Waltham, Massachusetts Tuesday, June 30, 2026, 13:00 Hrs [IST] Viridian Therape ...

Hormones are the body's chemical messengers that play a vital role in regulating a multitude of bodily functions. They are ...

An Iowa watchdog group says the EPA has stalled, or even scuttled, a nitrate review tied to health risks in drinking water.

As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the ...

Roche RHHBY announced that the FDA has accepted and granted priority review to its supplemental biologics license application ...

Lumvoa (veligrotug-vvze) is now FDA-approved to treat thyroid eye disease regardless of activity or duration, offering a new therapeutic option for both active and chronic phases. The Food and Drug ...